Icosagen Chooses Genedata Biologics to Digitalize Recombinant Antibody Discovery

Leading CRDMO implements market-leading platform to streamline its biotherapeutics discovery workflow and data exchange with biopharma customers

Basel, Switzerland—Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Icosagen, a research-driven organization providing services for the discovery and production of mammalian cell-derived biopharmaceuticals, has deployed Genedata Biologics® to digitalize and automate their recombinant antibodies discovery services in Europe and the U.S.“We were looking for a solution with out-of-the-box functionality tailored for large molecule R&D and chose Genedata Biologics because it has everything we need to digitalize our antibody discovery and protein manufacturing operations,” said Mart Ustav Jr., Ph.D., Chief Scientific Officer of Icosagen. “Since many of the biopharma and biotechs we work with as a CRDMO also use Genedata, it makes it even easier to exchange data with our customers. We are also very pleased with Genedata’s support and global presence, which gives us local access to support our operations both in Europe and the U.S.”Icosagen Cell Factory has custom-tailored services from discovery, hit-to-lead finding, pre-clinical candidate selection, up to early-stage clinical candidate development to provide recombinant antibodies and proteins to the biopharmaceutical and biotechnology industry. Genedata Biologics is used to automate and digitalize the full end-to-end discovery process at Icosagen, streamlining library generation, phage display selection and B-Cell screening, cloning and expression, IgG reformatting, lead characterization and developability assessment, candidate selection, and manufacturing along with cell line development.“When I first met Genedata scientists at a conference, I was impressed with their deep level of understanding of antibody discovery processes, and their suggestions on how Icosagen could increase throughput and improve R&D operational efficiency,” said Joan Teyra, Ph.D., Principal Scientist at Icosagen. “This expertise was confirmed during deployment and roll-out of the Genedata platform. Genedata is helping us to get up and running with spot-on suggestions on how to best streamline our processes and improve data quality.”“We are excited that Icosagen, a distinguished CRDMO, has chosen Genedata Biologics to digitalize their antibody operations,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Since Genedata Biologics is purpose-built for biotherapeutics and the platform of choice among top biopharma and biotech companies, more and more CRDMOs are adopting our platform to streamline operations and more easily share information with their biopharma customers.”About Icosagen CRDMOIcosagen is a research-driven contract research, development and manufacturing organization for biopharmaceutical, and biotechnology industries, focused on the production of functional recombinant proteins and antibody discovery. Icosagen’s unique CRDMO concept allows seamless transitions from transient R&D milligrams into stable high-producing cell lines and GMP manufacturing in several hundred-liter scale. Project and molecule know-how therefore stays in one single facility with one team and under one legal framework.  www.icosagen.com

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.

[www.genedata.com]www.genedata.comLinkedIn | Twitter | YouTubeContact

Allison KurzGenedataPublic Relations[email protected]


The statements in this press release to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the company’s products and services. Readers are cautioned not to place undue reliance to forward-looking statements, which speak only as the date hereof. The Company undertakes no obligation to release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after date hereof or to reflect the occurrence of unanticipated events.All Products and service names mentioned are trademarks of their respective companies.

< | >